Investor Presentation Full Year 2021
6
Investor presentation Full year 2021
Diabetes value market leadership increased by 0.8%-points to
30.1%
Novo Nordisk global diabetes value market share
Diabetes value market leadership expansion
driven by the GLP-1 franchise
60%
⚫Diabetes
GLP-1
-Insulin
52.7%
50.4%
50%
47.5%
44.4%
44.3%
43.8%
40%
30%
28.6%
29.3%
30.1%
•
0%
2018
2019
2020
2021
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Source: IQVIA MAT, Nov 2021 (Spot rate)
Note: Sales growth rates are at CER
Novo NordiskⓇ
Diabetes care sales grew by 13% with global value market share
increase driven by GLP-1 market share gains in both IO and NAO
Insulin volume market share has decreased from 47.3% to 47.1% in the
last 12 months
GLP-1 value market share has increased by 2.3%-points in the last 12
months, driven by:
OzempicⓇ launches and uptake in 72 countries
RybelsusⓇ uptake in North America Operations and launches in
International OperationsView entire presentation